Is VTUS a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

297 people get VTUS articles and Market Currents by email alert.

Get email alerts on VTUS »

HEADLINES:

Ventrus Biosciences Announces Poster Presentation on the Quality of Compounded Topical Diltiazem Hydrochloride Formulations for Anal Fissure at the American Pharmacists Association Meeting

GlobeNewswire (Mar 1, 2013)
Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference

GlobeNewswire (Feb 11, 2013)
Ventrus Biosciences Announces Full Exercise of Overallotment Option by Underwriters

GlobeNewswire (Feb 7, 2013)
Ventrus Biosciences Announces $20 Million Financing

GlobeNewswire (Jan 30, 2013)
Ventrus Biosciences Announces Proposed Public Offerings of Common Stock and Series A Convertible Preferred Stock

GlobeNewswire (Jan 29, 2013)
Ventrus Biosciences Reports Third Quarter 2012 Financial Results

GlobeNewswire (Nov 13, 2012)
Ventrus Biosciences to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

GlobeNewswire (Nov 8, 2012)
Ventrus Biosciences Receives FDA Written Feedback, Targets NDA Filing for Diltiazem (VEN 307) in Anal Fissures Following Second Phase 3 Study

GlobeNewswire (Nov 5, 2012)
Ventrus Biosciences Appoints JP Benya Vice President, Commercial Operations and Business Development

GlobeNewswire (Sep 24, 2012)
Ventrus Biosciences to Present at Upcoming Investor Conferences in September

GlobeNewswire (Aug 29, 2012)
Ventrus Biosciences Reports Second Quarter 2012 Financial Results

GlobeNewswire (Aug 9, 2012)
4 Reasons To Buy Ventrus Biosciences - Update
Markus Aarnio • Thu, Jun 28, 2012 • 6 Comments
2 Riskier Companies I'm Considering Selling In The Short Term, And Buying In The Long Term
Matt Schilling • Mon, Jun 25, 2012 • 2 Comments
Ventrus Biosciences Announces Results From Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease

GlobeNewswire (Jun 25, 2012)
5 Near-Term, Low-Priced Bio-Catalyst Trades
Mike Havrilla • Tue, Jun 12, 2012 • 12 Comments
Russell 3000 U.S. Healthcare Additions For June 2012
EXPstocktrader • Mon, Jun 11, 2012 • 2 Comments
Weekly Stock Watch: Week Of June 11, 2012
VFC's Stock House • Mon, Jun 11, 2012
4 High-Growth Healthcare Stocks On Winning Streaks
Kapitall • Thu, Jun 7, 2012
Ventrus to Present at the Jefferies 2012 Global Healthcare Conference

GlobeNewswire (May 30, 2012)
4 Reasons To Buy Ventrus Biosciences
Markus Aarnio • Mon, May 21, 2012 • 4 Comments

To learn more about Seeking Alpha Pro, click here.

4 Reasons To Buy Ventrus Biosciences - Update
Markus Aarnio • Thu, Jun 28, 2012 • 6 Comments
4 Reasons To Buy Ventrus Biosciences
Markus Aarnio • Mon, May 21, 2012 • 4 Comments

2 Riskier Companies I'm Considering Selling In The Short Term, And Buying In The Long Term
Matt Schilling • Mon, Jun 25, 2012 • 2 Comments
5 Near-Term, Low-Priced Bio-Catalyst Trades
Mike Havrilla • Tue, Jun 12, 2012 • 12 Comments
Russell 3000 U.S. Healthcare Additions For June 2012
EXPstocktrader • Mon, Jun 11, 2012 • 2 Comments
Weekly Stock Watch: Week Of June 11, 2012
VFC's Stock House • Mon, Jun 11, 2012
4 High-Growth Healthcare Stocks On Winning Streaks
Kapitall • Thu, Jun 7, 2012
6 Low Debt Pharmaceutical Stocks Rated Buy Or Better
ZetaKap • Mon, May 14, 2012 • 2 Comments
End Of Week Bio-Pharma Catalyst Trade And Watch List
Scott Matusow • Fri, May 4, 2012 • 46 Comments
Thursday's Bio-Pharma Drug Approval And Catalyst Event List
Scott Matusow • Thu, May 3, 2012 • 5 Comments
12 Healthcare Companies Expecting May Catalysts
Spencer Knight • Tue, May 1, 2012 • 9 Comments
Hedge Funds Love These 9 Rebounding Biotech Stocks
Kapitall • Sat, Jan 7, 2012 • 3 Comments
Biotech Class Of 2010: IPOs Revisited
Steven Breazzano • Wed, Jan 4, 2012 • 3 Comments
Biotech Focused Hedge Fund RA Capital's Top Q3 Picks
GuruFundPicks • Sun, Nov 20, 2011 • 3 Comments
17 High-Growth Healthcare Stocks Being Bought Up By Hedge Funds
Kapitall • Sun, Nov 20, 2011 • 2 Comments
IPO Market Slow But Still Healthy
IPO Candy • Thu, Jun 2, 2011
IPO Roundup: What's Candy and What's Bubble Gum
IPO Candy • Wed, May 4, 2011 • 4 Comments
Two Biotech IPOs Ahead This Week
IPOdesktop • Sun, Dec 12, 2010

There are no Transcripts on VTUS.

Ventrus Biosciences Announces Poster Presentation on the Quality of Compounded Topical Diltiazem Hydrochloride Formulations for Anal Fissure at the American Pharmacists Association Meeting

GlobeNewswire (Mar 1, 2013)
Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference

GlobeNewswire (Feb 11, 2013)
Ventrus Biosciences Announces Full Exercise of Overallotment Option by Underwriters

GlobeNewswire (Feb 7, 2013)
Ventrus Biosciences Announces $20 Million Financing

GlobeNewswire (Jan 30, 2013)
Ventrus Biosciences Announces Proposed Public Offerings of Common Stock and Series A Convertible Preferred Stock

GlobeNewswire (Jan 29, 2013)
Ventrus Biosciences Reports Third Quarter 2012 Financial Results

GlobeNewswire (Nov 13, 2012)
Ventrus Biosciences to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

GlobeNewswire (Nov 8, 2012)
Ventrus Biosciences Receives FDA Written Feedback, Targets NDA Filing for Diltiazem (VEN 307) in Anal Fissures Following Second Phase 3 Study

GlobeNewswire (Nov 5, 2012)
Ventrus Biosciences Appoints JP Benya Vice President, Commercial Operations and Business Development

GlobeNewswire (Sep 24, 2012)
Ventrus Biosciences to Present at Upcoming Investor Conferences in September

GlobeNewswire (Aug 29, 2012)
Ventrus Biosciences Reports Second Quarter 2012 Financial Results

GlobeNewswire (Aug 9, 2012)
Movers & Shakers: Monday’s biggest gaining and declining stocks

at MarketWatch.com (Jun 25, 2012)
Ventrus Biosciences Announces Results From Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease

GlobeNewswire (Jun 25, 2012)
Ventrus to Present at the Jefferies 2012 Global Healthcare Conference

GlobeNewswire (May 30, 2012)
Ventrus to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

GlobeNewswire (May 15, 2012)
Movers & Shakers: Monday’s top gaining and declining stocks

at MarketWatch.com (May 14, 2012)
Stocks to Watch: GRPN, BBY & More

at CNBC.com (May 14, 2012)
Ventrus Biosciences Announces Positive Results From Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures

GlobeNewswire (May 14, 2012)
Ventrus Biosciences Reports First Quarter 2012 Financial Results

GlobeNewswire (May 9, 2012)
Ventrus to Present at the 37th Annual Deutsche Bank Health Care Conference

GlobeNewswire (May 1, 2012)

VTUS vs. ETF Alternatives

Company Description

Currently, there's no company description for VTUS.

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, January 30, 12:45 PM Midday top 10 gainers: MERU +40%. CWBC +21%. BIOC +19%. MGAM +17%. FSL +17%. HTCH +17%. DLHC +17%. CPNO +14%. USAK +14%. IBCP +14%.
Midday top 10 Losers: VTUS -21%. KTCC -18%. MTOR -16%. HA -13%. ATTU -12%. CODE -12%. CEVA -12%. AUDC -11%. TRMD -10%. UPI -9%. 3 Comments [On the Move]
Tuesday, January 29, 5:45 PM Ventrus Biosciences (VTUS) announces a concurrent secondary offering to sell shares of its common stock, and shares of its Series A Convertible Preferred Stock in a separate underwritten public offering. Shares -7% AH. Comment! [Healthcare, On the Move]
Tuesday, January 29, 12:45 PM Midday top 10 gainers: MLNK +32%. KERX +30%. SOMH +25%. VTUS +24%. MHH +14%. SWIR +14%. AEZS +11%. CNIT +11%. IBCP +10%. SSBI +10%.
Midday top 10 Losers: OXF -31%. ANAC -21%. VMW -20%. SANM -18%. OCZ -18%. LXK -15%. CTC -13%. GIG -12%. NTGR -11%. SHIP -11%. Comment! [On the Move]
Tuesday, January 29, 12:44 PM Ventrus Biosciences (VTUS +26%) continues on a tear today, extending gains for a second day after the biotech company confirmed last week that it has sufficient cash to complete development of VEN307, its anal fissure drug candidate. Comment! [Healthcare, On the Move]
Wednesday, November 14, 2012, 2:35 PM Ventrus Biosciences (VTUS +5.3%) moves higher today, offsetting some of the losses from a lower than expected Q3 EPS yesterday. Cantor Fitzgerald thinks the results were "meaningless" and the stock is extremely undervalued. The firm believes the market is too deeply discounting the company's diltiazem hydrochloride cream, a treatment for anal fissures currently in Phase 3 testing. The drug suffered a setback recently when the FDA said it required a second Phase 3 study, but Cantor believes it should be market ready by the end of 2014. Comment! [Healthcare, Earnings, On the Move]
Monday, November 5, 2012, 3:24 PM Ventrus Biosciences Inc. (VTUS -9.8%) slides after getting FDA feedback requiring a second Phase 3 study of its diltiazem hydrochloride cream - a treatment for anal fissures - before any new drug application can be filed. The drug developer says it expects to file the NDA following completion of the second Phase 3 study, with results expected early Q4 2013, and expects to file an NDA late in Q4 2013 with an anticipated PDUFA date near the end of 2014. Comment! [Healthcare, On the Move]
Monday, November 5, 2012, 12:45 PM Midday top 10 gainers: NVGN +50%. ICAD +43%. NTE +36%. HMNY +19%. BMRN +30%. OPTT +25%. VRNG +23%. EQU +15%. BEE +13%. BITA +12%.
Top 10 Losers: EBIX -22%. HGSH -19%. RDN -14%. PCYC -12%. MEAD -15%. VTUS -10%. PKBK -10%. COCO -9%. PGRX -9%. ENZ -9%. 1 Comment [On the Move]
Monday, June 25, 2012, 9:06 AM Premarket gainers: LXRX +8%. TEVA +7%. QSFT +6%.
Losers: VTUS -53%. MNTA -23%. SHPGY -12%. CEL -7%. ALU -6%. ARNA -6%. NOK -5%. ING -5%. Comment! [On the Move]
Monday, June 25, 2012, 8:24 AM Ventrus Biosciences (VTUS) plummets 58% after the company says its iferanserin drug for hemorrhoidal disease failed to meet the primary end points of a phase 3 trial, the elimination of bleeding, itching and pain. Ventrus has no plans to keep working on the treatment and will instead focus on its other compounds. (PR) Comment! [Healthcare, On the Move]
Monday, May 14, 2012, 9:26 AM Ventrus Biosciences (VTUS) +14.6% premarket after it says Phase III trials of its Diltiazem treatment for the relief of pain associated with anal fissures showed significant improvements over placebos. (PR) Comment! [Healthcare, On the Move]

mraswindell
Waiting for bounce from VTUS $4.30
6/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
$$ 6 Low Debt Pharmaceutical Stocks Rated Buy Or Better http://bit.ly/L0WSca $ASTX $ECTE $IPXL $KERX $RIGL $VTUS @ZetaKap #pharma
5/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
$$ Just posted: 6 Low Debt Pharmaceutical Stocks Rated Buy Or Better http://bit.ly/L0WSca $ASTX $ECTE $IPXL $KERX $RIGL $VTUS @ZetaKap
5/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

jfly_80
lets go VTUS
4/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
Premarket Gainers: $GLBC, $AMMD, $LVLT, $YONG, $TYC, $BIIB, $VTUS, $AONEQ.PK, $SHZ, $BIDU
4/11/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

VTUS Ventrus Biosciences Inc

VTUS

Ventrus Biosciences Inc